組織診断の世界市場予測（～2022年）：消耗品、装置、技術、疾患、エンドユーザー...市場調査レポートについてご紹介

TABLE OF CONTENTS

1 INTRODUCTION 15
1.1 OBJECTIVES OF THE STUDY 15
1.2 MARKET DEFINITION 15
1.3 MARKET SCOPE 16
1.3.1 MARKETS COVERED 16
1.3.2 YEARS CONSIDERED FOR THE STUDY 17
1.4 CURRENCY 17
1.5 LIMITATIONS 17
1.6 STAKEHOLDERS 17
2 RESEARCH METHODOLOGY 18
2.1 RESEARCH DATA 18
2.1.1 SECONDARY DATA 19
2.1.1.1 Key data from secondary sources 19
2.1.2 PRIMARY DATA 20
2.1.2.1 Key data from primary sources 20
2.1.2.2 Breakdown of primaries 21
2.2 MARKET SIZE ESTIMATION 21
2.2.1 BOTTOM-UP APPROACH 22
2.2.2 TOP-DOWN APPROACH 23
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 24
2.4 RESEARCH ASSUMPTIONS 25
3 EXECUTIVE SUMMARY 26
4 PREMIUM INSIGHTS 30
4.1 TISSUE DIAGNOSTICS: MARKET OVERVIEW 30
4.2 GEOGRAPHIC ANALYSIS: TISSUE DIAGNOSTICS MARKET IN ASIA, BY COUNTRY AND TECHNOLOGY 31
4.3 GLOBAL TISSUE DIAGNOSTICS MARKET, BY END USER 32
4.4 GEOGRAPHICAL SNAPSHOT OF THE GLOBAL TISSUE DIAGNOSTICS MARKET 33
5 MARKET OVERVIEW 34
5.1 INTRODUCTION 34
5.2 MARKET DYNAMICS 34
5.2.1 DRIVERS 35
5.2.1.1 Rising incidence of cancer 35
5.2.1.2 Growing healthcare expenditure 35
5.2.1.3 Improving infrastructure for cancer diagnosis 36
5.2.1.4 Technological advancements in tissue diagnostics 37
5.2.2 RESTRAINTS 37
5.2.2.1 High degree of consolidation 37
5.2.3 OPPORTUNITIES 38
5.2.3.1 Emerging markets 38
5.2.3.2 Growing demand for personalized medicine 38
5.2.3.3 Rising number of clinical trials for cancer drugs 39
5.2.4 CHALLENGES 39
5.2.4.1 Stringent regulatory requirements 39
5.2.4.2 Lack of infrastructure and low awareness in middle- and low- income countries 39
5.2.5 TRENDS 40
5.2.5.1 Increasing number of reagent rental agreements 40
6 TISSUE DIAGNOSTICS MARKET, BY PRODUCT 41
6.1 INTRODUCTION 42
6.2 CONSUMABLES 43
6.2.1 ANTIBODIES 44
6.2.2 KITS 44
6.2.3 REAGENTS 45
6.2.4 PROBES 46
6.3 INSTRUMENTS 46
6.3.1 SLIDE-STAINING SYSTEMS 47
6.3.2 SCANNERS 48
6.3.3 TISSUE-PROCESSING SYSTEMS 49
6.3.4 OTHER INSTRUMENTS 49
7 TISSUE DIAGNOSTICS MARKET, BY TECHNOLOGY 51
7.1 INTRODUCTION 52
7.2 IMMUNOHISTOCHEMISTRY (IHC) 53
7.3 IN SITU HYBRIDIZATION (ISH) 54
7.4 DIGITAL PATHOLOGY AND WORKFLOW MANAGEMENT 55
7.5 SPECIAL STAINING 56
8 TISSUE DIAGNOSTICS MARKET, BY DISEASE 58
8.1 INTRODUCTION 59
8.2 BREAST CANCER 60
8.3 GASTRIC CANCER 61
8.4 LYMPHOMA 62
8.5 PROSTATE CANCER 63
8.6 NON-SMALL CELL LUNG CANCER (NSCLC) 64
8.7 OTHER DISEASES 65
9 TISSUE DIAGNOSTICS MARKET, BY END USER 66
9.1 INTRODUCTION 67
9.2 HOSPITALS 68
9.3 RESEARCH LABORATORIES 69
9.4 PHARMACEUTICAL COMPANIES 70
9.5 CONTRACT RESEARCH ORGANIZATIONS 71
9.6 OTHER END USERS 72
10 TISSUE DIAGNOSTICS MARKET, BY REGION 73
10.1 INTRODUCTION 74
10.2 NORTH AMERICA 75
10.2.1 US 81
10.2.2 CANADA 83
10.3 EUROPE 85
10.3.1 GERMANY 91
10.3.2 UK 93
10.3.3 FRANCE 95
10.3.4 ITALY 97
10.3.5 SPAIN 99
10.3.6 REST OF EUROPE (ROE) 101
10.4 ASIA 103
10.4.1 CHINA 108
10.4.2 JAPAN 110
10.4.3 INDIA 112
10.4.4 REST OF ASIA (ROA) 113
10.5 REST OF THE WORLD (ROW) 115
11 COMPETITIVE LANDSCAPE 121
11.1 INTRODUCTION 121
11.2 MARKET SHARE ANALYSIS 121
12 COMPANY PROFILES 123
(Business Overview, Strength of product Portfolio, Business Strategy Excellence, Recent Developments,)*
12.1 ROCHE 123
12.2 DANAHER 125
12.3 THERMO FISHER SCIENTIFIC 128
12.4 ABBOTT 131
12.5 AGILENT TECHNOLOGIES 133
12.6 MERCK 136
12.7 SAKURA FINETEK JAPAN 138
12.8 ABCAM 140
12.9 BD 142
12.10 QIAGEN 144
12.11 BIO SB 146
12.12 BIOGENEX 148
12.13 CELL SIGNALING TECHNOLOGY 150
*Details on Business Overview, Strength of product Portfolio, Business Strategy Excellence, Recent Developments, might not be captured in case of unlisted companies.
13 APPENDIX 152
13.1 INDUSTRY INSIGHTS 152
13.2 DISCUSSION GUIDE 153
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 156
13.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 158
13.5 AVAILABLE CUSTOMIZATIONS 159
13.6 RELATED REPORTS 159
13.7 AUTHOR DETAILS 160